{"id":2994,"date":"2026-08-11T11:39:39","date_gmt":"2026-08-11T18:39:39","guid":{"rendered":"https:\/\/www.ultalabtests.com\/blog\/?p=2994"},"modified":"2026-08-11T21:33:23","modified_gmt":"2026-08-12T04:33:23","slug":"cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers","status":"publish","type":"post","link":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/","title":{"rendered":"Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Cancer blood tests include routine blood counts and chemistry tests, selected tumor markers, protein studies, and specialized molecular assays. They can support risk discussions, symptom evaluation, pretreatment baselines, treatment-safety monitoring, response assessment, and follow-up. However, no single blood test can diagnose or rule out most cancers by itself.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Key limitation:<\/strong> A high tumor marker does not automatically mean cancer, and a normal marker does not guarantee that cancer is absent. Benign conditions can raise many markers, some cancers do not release measurable amounts, and the meaning of a result depends on why the test was ordered, the assay used, symptoms, risk factors, imaging, pathology, treatment history, and the trend over time.<sup><a href=\"#ref-1\">1<\/a>, <a href=\"#ref-2\">2<\/a><\/sup><\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/01-cancer-blood-tests-tumor-markers-hero.webp?quality=100&amp;resize=1024%2C576&amp;ssl=1\" alt=\"Clinician and patient reviewing cancer-related blood test results with symbols for imaging, pathology, monitoring, and follow-up.\"\/><figcaption class=\"wp-element-caption\">Cancer blood tests can support evaluation and monitoring, but no result diagnoses or excludes cancer on its own.<\/figcaption><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>On this page<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"#knowledge-center\">Knowledge Center and related pillars<\/a><\/li>\n\n\n\n<li><a href=\"#key-facts\">Key facts<\/a><\/li>\n\n\n\n<li><a href=\"#what-are-cancer-blood-tests\">What cancer blood tests are<\/a><\/li>\n\n\n\n<li><a href=\"#screening-diagnostic-monitoring\">Screening, diagnostic support, and monitoring<\/a><\/li>\n\n\n\n<li><a href=\"#hormone-sensitive-cancers\">Hormone-sensitive cancers<\/a><\/li>\n\n\n\n<li><a href=\"#symptoms-risk-scenarios\">Symptoms, risks, and testing scenarios<\/a><\/li>\n\n\n\n<li><a href=\"#testing-tiers\">Testing tiers<\/a><\/li>\n\n\n\n<li><a href=\"#detailed-tests\">Detailed tests and tumor-marker crosswalk<\/a><\/li>\n\n\n\n<li><a href=\"#elevated-marker\">What to do with an elevated marker<\/a><\/li>\n\n\n\n<li><a href=\"#routine-screening-versus-markers\">Routine screening versus tumor markers<\/a><\/li>\n\n\n\n<li><a href=\"#liquid-biopsy\">Liquid biopsy, ctDNA, MRD, and multi-cancer tests<\/a><\/li>\n\n\n\n<li><a href=\"#preparation\">Preparation and interferences<\/a><\/li>\n\n\n\n<li><a href=\"#understand-results\">Understanding results and trends<\/a><\/li>\n\n\n\n<li><a href=\"#faq\">Frequently asked questions<\/a><\/li>\n\n\n\n<li><a href=\"#references\">References<\/a><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Part of the Ulta Lab Tests Knowledge Center<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Start with <a href=\"https:\/\/www.ultalabtests.com\/blog\/lab-testing-knowledge-center\/complete-guide-to-lab-tests-and-blood-work\/\">The Complete Guide to Lab Tests and Blood Work<\/a> for an overview of specimens, panels, screening, diagnostic support, and monitoring. Use <a href=\"https:\/\/www.ultalabtests.com\/blog\/lab-testing-knowledge-center\/how-to-read-lab-results\/\">How to Read and Understand Your Lab Results<\/a> for reference intervals, units, flags, biological variation, and trends. Review <a href=\"https:\/\/www.ultalabtests.com\/blog\/lab-testing-knowledge-center\/direct-access-lab-testing\/\">Direct-Access Lab Testing: How It Works and What to Expect<\/a> before ordering, preparing, collecting a specimen, or deciding how to follow up.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Related health-category pillars include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/blood-disorders\/cbc-anemia-blood-tests\/\">CBC and Anemia Blood Tests<\/a> for blood-cell patterns, iron status, vitamin B12, folate, and anemia follow-up.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/mens-health\/all-mens-health\/mens-health-blood-tests\/\">Men's Health Blood Tests<\/a> for prostate, testosterone, and related men's health testing.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/liver\/liver-function-tests\/\">Liver Function Tests<\/a> for liver enzymes, bilirubin, proteins, and metabolic liver patterns.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/inflammation\/inflammation-autoimmune-blood-tests\/\">Inflammation and Autoimmune Blood Tests<\/a> for CRP, ESR, ANA, and inflammatory patterns that can affect interpretation.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/genomic-testing\/genetic-genomic-testing\/\">Genetic and Genomic Testing<\/a> for germline risk, pharmacogenomics, and the distinction between inherited and tumor-acquired variants.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Key Facts About Cancer Blood Tests<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Test and quick facts<\/th><th>What it shows and how it is used<\/th><th>Preparation, influences, and limitations<\/th><\/tr><\/thead><tbody><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">Complete blood count with differential and platelets<\/a><br><strong>Use status:<\/strong> Common or first-line; monitoring<\/th><td>Measures red cells, white cells, platelets, and cell indices. It may help evaluate anemia, infection or marrow patterns, establish a baseline, and monitor treatment effects.<\/td><td>Usually no fasting. Hydration, infection, medicines, altitude, pregnancy, and timing within a treatment cycle can matter. An abnormal CBC is nonspecific, and many cancers cause no CBC change.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">Comprehensive metabolic panel<\/a><br><strong>Use status:<\/strong> Common or first-line; monitoring<\/th><td>Assesses selected kidney, liver, electrolyte, protein, calcium, and glucose measures. It may identify organ effects or support treatment-safety monitoring.<\/td><td>Follow the order-specific fasting instructions. Hydration, medicines, supplements, recent illness, and specimen hemolysis may affect results. A CMP does not locate or diagnose a tumor.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free and total PSA<\/a><br><strong>Use status:<\/strong> Risk-based or targeted; monitoring<\/th><td>Supports informed prostate-screening decisions, evaluation of selected prostate concerns, and monitoring after a prostate-cancer diagnosis or treatment.<\/td><td>Prostate enlargement, inflammation, infection, ejaculation, procedures, urinary retention, and some medicines can affect interpretation. No single PSA value proves or excludes cancer.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a><br><strong>Use status:<\/strong> Targeted; monitoring<\/th><td>Most commonly supports monitoring in ovarian cancer and selected evaluation of a suspicious pelvic mass.<\/td><td>Menstruation, pregnancy, endometriosis, fibroids, pelvic inflammation, and liver disease may raise it. It is not recommended as routine screening for average-risk asymptomatic people.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-15-3\">CA 15-3<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-27-29\">CA 27.29<\/a><br><strong>Use status:<\/strong> Monitoring; specialist-directed<\/th><td>May be followed in selected people with known breast cancer, especially advanced disease, when the marker is informative for that individual.<\/td><td>Benign conditions and other cancers can affect results, and early or localized breast cancer may not raise them. They do not replace mammography, diagnostic imaging, biopsy, or tumor-tissue biomarker testing.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a><br><strong>Use status:<\/strong> Monitoring<\/th><td>Provides a pretreatment baseline and may support treatment-response or recurrence monitoring, especially in colorectal cancer.<\/td><td>Smoking and several liver, digestive, inflammatory, or metabolic conditions can raise CEA. It is not a colorectal-cancer screening or diagnostic test by itself.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a><br><strong>Use status:<\/strong> Targeted; monitoring<\/th><td>May support selected liver-cancer and germ-cell-tumor evaluation, staging context, prognosis, or monitoring.<\/td><td>Pregnancy and chronic liver disease are important confounders. AFP can be elevated without cancer and can remain normal when cancer is present.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">quantitative hCG<\/a><br><strong>Use status:<\/strong> Targeted; monitoring<\/th><td>Used in selected pancreaticobiliary, gastrointestinal, trophoblastic, and germ-cell-tumor settings.<\/td><td>Biliary obstruction, pancreatitis, pregnancy, and other clinical circumstances are critical. Neither is a universal cancer-screening test, and some people do not produce CA 19-9.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-a\">Inhibin A<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-b\">Inhibin B<\/a><br><strong>Use status:<\/strong> Specialist-directed; monitoring<\/th><td>May aid evaluation or monitoring of selected ovarian sex cord-stromal tumors, including granulosa-cell tumors, especially when informative at baseline.<\/td><td>These are not general ovarian-cancer screening tests. Reproductive status, tumor biology, assay method, and specialist context matter.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">serum immunofixation<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">free light chains<\/a><br><strong>Use status:<\/strong> Targeted; specialist-directed; monitoring<\/th><td>Evaluate a suspected monoclonal protein or plasma-cell disorder and monitor selected known disease.<\/td><td>Inflammation, liver disease, kidney function, medications, and nonmalignant monoclonal gammopathy may affect results. Diagnosis requires a broader clinical workup.<\/td><\/tr><tr><th>Circulating tumor DNA and other liquid-biopsy assays<br><strong>Use status:<\/strong> Specialist-directed, disease-specific, or emerging<\/th><td>Depending on the exact assay, may support treatment selection, molecular residual-disease assessment, a defined disease-specific screening use, or research.<\/td><td>The term covers very different technologies and indications. Regulatory status, validation, intended population, and required diagnostic follow-up must be checked assay by assay.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">What Are Cancer Blood Tests and Tumor Markers?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Cancer is not one disease, and there is no single blood test that reliably finds every cancer. The phrase <em>cancer blood tests<\/em> includes several different tools:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Foundational laboratory tests<\/strong>, such as a <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a> or <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, that may show anemia, abnormal blood-cell counts, calcium changes, liver or kidney dysfunction, protein abnormalities, or treatment toxicity.<\/li>\n\n\n\n<li><strong>Circulating proteins or substances<\/strong>, such as <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">beta-hCG<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-15-3\">CA 15-3<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-27-29\">CA 27.29<\/a>, and selected inhibin tests.<\/li>\n\n\n\n<li><strong>Protein-pattern studies<\/strong>, including <a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">serum protein electrophoresis<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">serum immunofixation<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">serum free light chains<\/a>, used in selected plasma-cell-disorder evaluations.<\/li>\n\n\n\n<li><strong>Tumor-tissue and blood-based molecular biomarkers<\/strong> used to select targeted therapy, assess prognosis, or monitor molecular disease in specific cancer settings.<\/li>\n\n\n\n<li><strong>Emerging or disease-specific detection assays<\/strong> that analyze cell-free DNA, methylation, fragmentation, proteins, or other signals.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">A tumor marker may be made by cancer cells or by normal cells responding to cancer or a noncancerous condition. This explains the central limitation: a marker may be high without cancer, and a person may have cancer without a high marker. Results are most useful when the purpose of testing is defined before the blood draw and the interpretation includes symptoms, risk, examination, imaging, pathology, treatment history, and prior values.<sup><a href=\"#ref-1\">1<\/a>, <a href=\"#ref-2\">2<\/a><\/sup><\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/03-cancer-blood-test-types-overview.webp?quality=100&amp;resize=1024%2C576&amp;ssl=1\" alt=\"Four groups of cancer-related blood tests: CBC and CMP, tumor markers, protein studies, and molecular tests such as circulating tumor DNA.\"\/><figcaption class=\"wp-element-caption\">Cancer-related testing includes foundational blood counts and chemistry tests, traditional tumor markers, plasma-cell studies, and selected molecular assays.<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Why the Intended Use Matters<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Confusing screening with diagnosis or monitoring can cause harm. Broad testing in people with a low likelihood of disease can produce false-positive results, anxiety, repeat blood draws, imaging, invasive procedures, and cost without a demonstrated improvement in outcomes. A reassuring marker can also create false confidence and delay evaluation of a persistent symptom or abnormal imaging finding.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Focused testing is more useful when it answers a defined question: Is the bone marrow tolerating treatment? Is kidney or liver function changing? Was a marker elevated before treatment, and is the trend consistent with the rest of the clinical picture? Does a person considering PSA screening understand the potential benefits and harms? Is an abnormal protein pattern contributing to unexplained anemia, kidney dysfunction, high total protein, neuropathy, or bone symptoms?<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A pretreatment baseline matters when a result will be followed over time. A marker that was never elevated may be a poor monitoring tool for that individual. Trends are also harder to compare when the laboratory, assay method, unit, or clinical circumstances change.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Screening Versus Diagnostic Support Versus Monitoring<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This framework is educational and is not a diagnostic or treatment algorithm.<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/04-cancer-screening-diagnostic-support-monitoring.webp?quality=100&amp;resize=1024%2C576&amp;ssl=1\" alt=\"Comparison of cancer blood tests used for screening, diagnostic support, and monitoring known disease over time.\"\/><figcaption class=\"wp-element-caption\">The same laboratory result can mean something different when used for screening, diagnostic support, or monitoring.<\/figcaption><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Use and status<\/th><th>What the test is being asked to do<\/th><th>What the result cannot do alone<\/th><\/tr><\/thead><tbody><tr><th><strong>Population screening<\/strong><br><strong>Use status:<\/strong> Guideline-defined<\/th><td>Tests people without symptoms to identify who may need diagnostic follow-up. Established examples include mammography, cervical screening, colorectal screening, and low-dose CT for eligible people; PSA requires an informed, individualized decision.<\/td><td>A screening result does not diagnose cancer. Benefit depends on the population, interval, follow-up pathway, and balance of benefits and harms.<\/td><\/tr><tr><th><strong>Risk assessment<\/strong><br><strong>Use status:<\/strong> Risk-based<\/th><td>Uses family history, exposures, inherited variants, age, and other factors to decide whether surveillance or prevention should change.<\/td><td>Risk information does not show that cancer is currently present. Germline testing and tumor testing answer different questions.<\/td><\/tr><tr><th><strong>Diagnostic support<\/strong><br><strong>Use status:<\/strong> Targeted<\/th><td>Adds information when symptoms, a mass, abnormal imaging, or another finding is already concerning. CBC, CMP, selected tumor markers, and protein studies may help characterize consequences or narrow next steps.<\/td><td>Blood testing does not replace examination, imaging, endoscopy, bone-marrow evaluation, biopsy, or pathology.<\/td><\/tr><tr><th><strong>Baseline and prognostic context<\/strong><br><strong>Use status:<\/strong> Specialist-directed<\/th><td>Documents organ function and selected markers before treatment. In defined cancers, a marker may contribute to stage or prognosis when combined with other evidence.<\/td><td>A marker does not determine stage, prognosis, or treatment by itself.<\/td><\/tr><tr><th><strong>Treatment-response monitoring<\/strong><br><strong>Use status:<\/strong> Monitoring<\/th><td>Follows a previously informative marker and checks blood counts, kidney function, liver function, electrolytes, and other treatment-safety measures.<\/td><td>A falling or rising marker does not prove response or progression without symptoms, examination, imaging, and the oncology plan.<\/td><\/tr><tr><th><strong>Recurrence monitoring<\/strong><br><strong>Use status:<\/strong> Disease-specific monitoring<\/th><td>Uses serial markers or selected molecular assays after treatment when guidelines or the treating team define a role.<\/td><td>A concerning trend usually prompts confirmation. It does not establish recurrence on its own.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">What Laboratory Testing May Reveal\u2014and What It Cannot Establish<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Laboratory finding<\/th><th>What it may reveal<\/th><th>What it cannot establish by itself<\/th><\/tr><\/thead><tbody><tr><th>Blood-cell counts or cell-index abnormalities<\/th><td>May identify anemia, low platelets, high or low white-cell counts, or other patterns.<\/td><td>Cannot establish the cause. History, repeat testing, smear review, nutritional evaluation, flow cytometry, bone-marrow testing, or other targeted workup may be needed.<\/td><\/tr><tr><th>Organ-function and metabolic abnormalities<\/th><td>May identify changes in liver, kidney, calcium, electrolytes, glucose, or proteins.<\/td><td>Cannot determine whether a solid tumor caused the change or where a tumor is located. Imaging, medication review, and specialist assessment may be needed.<\/td><\/tr><tr><th>A marker above the laboratory interval or a serial change<\/th><td>May signal that a defined follow-up question deserves attention.<\/td><td>Cannot prove cancer, response, progression, or recurrence. Method-consistent repeat testing, imaging, and sometimes biopsy may be required.<\/td><\/tr><tr><th>A monoclonal protein pattern or abnormal free-light-chain ratio<\/th><td>May support evaluation of a plasma-cell or related disorder.<\/td><td>Cannot distinguish MGUS, myeloma, amyloidosis, lymphoma, inflammation, or kidney-related change without additional criteria and evaluation.<\/td><\/tr><tr><th>A tumor-associated genomic alteration<\/th><td>May identify a treatment-associated biomarker in a validated setting.<\/td><td>Cannot guarantee that a therapy will work or that tissue testing is unnecessary.<\/td><\/tr><tr><th>A cancer signal on a disease-specific or multi-cancer assay<\/th><td>May identify a need for a coordinated diagnostic workup.<\/td><td>Cannot serve as pathology or establish the exact cancer site with certainty. A negative result does not exclude cancer.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/05-cancer-blood-tests-can-and-cannot-tell-you.webp?quality=100&amp;resize=1024%2C576&amp;ssl=1\" alt=\"Educational comparison of what cancer blood tests can and cannot tell a patient.\"\/><figcaption class=\"wp-element-caption\">Laboratory tests can reveal patterns and trends, but imaging, biopsy, pathology, and specialist review may be needed to determine what they mean.<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Hormone-Sensitive Cancers: Receptor Testing, Blood Hormones, and Tumor Markers<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A <em>hormone-sensitive<\/em> cancer depends in part on hormonal signaling for growth. A <em>hormone-producing<\/em> tumor may release hormones or related substances. These categories overlap in some cases, but they are not the same. Most importantly, neither term means that a routine hormone blood test can find the tumor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In breast cancer, estrogen-receptor and progesterone-receptor status is generally determined by testing tumor tissue obtained during a biopsy or surgery. Serum estrogen or progesterone levels do not establish whether a tumor is ER-positive or PR-positive.<sup><a href=\"#ref-3\">3<\/a><\/sup> In prostate cancer, androgen signaling can influence treatment, but a circulating testosterone result is not a prostate-cancer screening or diagnostic test.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Traditional tumor markers may still support selected monitoring questions. <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-15-3\">CA 15-3<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-27-29\">CA 27.29<\/a> may be followed in selected people with known breast cancer, while <a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-a\">Inhibin A<\/a> or <a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-b\">Inhibin B<\/a> may be used in selected ovarian sex cord-stromal-tumor settings. These uses are targeted and specialist-directed; they do not create a stand-alone early-detection pathway.<sup><a href=\"#ref-2\">2<\/a>, <a href=\"#ref-15\">15<\/a><\/sup><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Test or concept and use status<\/th><th>How it may be used<\/th><th>Critical limitation<\/th><\/tr><\/thead><tbody><tr><th><strong>ER, PR, HER2, and other tumor-tissue biomarkers<\/strong><br><strong>Use status:<\/strong> Specialist-directed tissue testing<\/th><td>Breast-cancer cells are commonly tested after biopsy or surgery to determine receptor and biomarker status and help plan treatment.<sup><a href=\"#ref-3\">3<\/a><\/sup><\/td><td>These are not routine serum hormone measurements. A blood estrogen or progesterone result does not establish whether a breast tumor is ER-positive or PR-positive.<\/td><\/tr><tr><th><strong>Circulating estrogen or progesterone<\/strong><br><strong>Use status:<\/strong> Selected endocrine or treatment context<\/th><td>May be measured for defined endocrine questions or in selected treatment-monitoring situations directed by the treating team.<\/td><td>Does not screen for breast cancer, diagnose a hormone-sensitive tumor, or substitute for receptor testing on tumor tissue.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-15-3\">CA 15-3<\/a><br><strong>Use status:<\/strong> Monitoring; specialist-directed<\/th><td>May be followed in selected people with known breast cancer, particularly advanced disease, when it is informative for that individual.<sup><a href=\"#ref-2\">2<\/a><\/sup><\/td><td>Not a breast-cancer screening or diagnostic test. A normal result does not rule out disease, and a change must be interpreted with imaging and the treatment plan.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-27-29\">CA 27.29<\/a><br><strong>Use status:<\/strong> Monitoring; specialist-directed<\/th><td>May support selected breast-cancer follow-up or monitoring when a baseline and clinical indication exist.<sup><a href=\"#ref-2\">2<\/a><\/sup><\/td><td>Does not replace mammography, diagnostic breast imaging, biopsy, or pathology. Benign conditions and other cancers may affect the result.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> and selected <a href=\"https:\/\/www.ultalabtests.com\/test\/testosterone-total-ms\">total testosterone<\/a> monitoring<br><strong>Use status:<\/strong> Risk-based or oncology-directed<\/th><td>PSA may support informed screening decisions and prostate-cancer monitoring. Testosterone may be monitored during selected androgen-deprivation treatment plans.<sup><a href=\"#ref-4\">4<\/a><\/sup><\/td><td>Androgen dependence does not make testosterone a prostate-cancer detection test. PSA and testosterone trends must be interpreted with treatment history, symptoms, examination, and imaging.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-a\">Inhibin A<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-b\">Inhibin B<\/a><br><strong>Use status:<\/strong> Specialist-directed; monitoring<\/th><td>May aid evaluation or follow-up of selected ovarian sex cord-stromal tumors, including granulosa-cell tumors, particularly when a marker was informative at diagnosis.<sup><a href=\"#ref-15\">15<\/a><\/sup><\/td><td>Not general ovarian-cancer screening tests. Reproductive status, menopause, tumor biology, assay method, and the specialist-defined purpose of testing matter.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Symptoms, Risk Factors, and Patient Scenarios<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Scenario and urgency<\/th><th>Laboratory tests that may add information<\/th><th>Nonlaboratory evaluation and limitations<\/th><\/tr><\/thead><tbody><tr><th><strong>Persistent fatigue, pallor, bruising, infections, or unexplained weight loss<\/strong><br><strong>Urgency:<\/strong> Prompt review if persistent; urgent for severe weakness, uncontrolled bleeding, or fever during cancer treatment<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC with differential<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a> may assess blood-cell and organ-function patterns. Additional anemia or hematology testing should be selected from the findings.<\/td><td>These symptoms have many noncancer causes. History, examination, repeat testing, imaging, or hematology evaluation may be needed.<\/td><\/tr><tr><th><strong>Visible blood in urine, stool, sputum, or vomit; unexplained vaginal bleeding<\/strong><br><strong>Urgency:<\/strong> Heavy bleeding, fainting, black stool, or coughing or vomiting blood may be an emergency<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/urinalysis-ua-complete\">complete urinalysis<\/a> may assess consequences or alternative explanations.<\/td><td>Do not substitute a tumor marker for prompt urologic, gastrointestinal, gynecologic, pulmonary, imaging, or endoscopic evaluation.<\/td><\/tr><tr><th><strong>New mass, enlarging lymph node, persistent focal pain, or nonhealing lesion<\/strong><br><strong>Urgency:<\/strong> Arrange prompt examination<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, and selected context-specific tests may add information.<\/td><td>Physical examination, ultrasound or other imaging, and biopsy may be required. Do not delay evaluation while waiting for a tumor-marker result.<\/td><\/tr><tr><th><strong>Jaundice, dark urine, pale stool, or persistent upper-abdominal pain<\/strong><br><strong>Urgency:<\/strong> Fever with jaundice, confusion, severe pain, or persistent vomiting requires urgent assessment<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a> can assess liver and metabolic patterns. <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a> belongs only in a defined professional pancreaticobiliary workup.<\/td><td>Gallstones, hepatitis, pancreatitis, medication injury, obstruction, and malignancy are among many possibilities. Imaging and gastroenterology or emergency evaluation may be needed.<\/td><\/tr><tr><th><strong>Urinary obstruction, blood in urine or semen, pelvic or back pain, or a prostate-screening decision<\/strong><br><strong>Urgency:<\/strong> Urinary retention, fever with urinary symptoms, or severe pain needs prompt care<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/urinalysis-ua-complete\">Urinalysis<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">total PSA<\/a>, and sometimes <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free and total PSA<\/a> may add information after clinical review.<\/td><td>Benign prostate enlargement, prostatitis, infection, and stones can cause similar findings. Examination, urology review, MRI, cystoscopy, or biopsy may be indicated.<\/td><\/tr><tr><th><strong>Persistent bloating, pelvic pressure, early satiety, or a pelvic mass<\/strong><br><strong>Urgency:<\/strong> Severe pain, fainting, acute bleeding, or pregnancy concerns require urgent evaluation<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, and selected <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a> testing may support a risk-informed evaluation.<\/td><td>Pelvic examination and ultrasound are central. CA-125 cannot diagnose ovarian cancer and is not routine screening for average-risk asymptomatic people.<\/td><\/tr><tr><th><strong>Unexplained anemia, kidney dysfunction, high total protein, bone pain, neuropathy, or recurrent fractures<\/strong><br><strong>Urgency:<\/strong> New weakness, spinal-cord symptoms, severe hypercalcemia symptoms, or acute kidney injury requires urgent care<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">serum immunofixation<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">free light chains<\/a>, and related testing may be considered.<\/td><td>Imaging, urine protein studies, bone-marrow evaluation, nephrology, neurology, or hematology review may be needed. An abnormal protein test is not automatically myeloma.<\/td><\/tr><tr><th><strong>Strong family history, early-onset cancers, multiple primary cancers, or a known familial variant<\/strong><br><strong>Urgency:<\/strong> Nonurgent unless symptoms are present, but planning should not be delayed indefinitely<\/th><td>Germline testing selected with genetic counseling may be appropriate. See <a href=\"https:\/\/www.ultalabtests.com\/blog\/genomic-testing\/genetic-genomic-testing\/\">Genetic and Genomic Testing<\/a>.<\/td><td>Hereditary risk testing does not diagnose a current cancer. A negative limited panel does not erase a strong family history.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Testing-Tier Overview<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Common or First-Line Tests<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/urinalysis-ua-complete\">urinalysis<\/a>, and other symptom-directed tests often assess blood-cell patterns, organ effects, metabolic changes, or treatment safety. They are not cancer panels and cannot exclude malignancy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Risk-Based or Targeted Tests<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free and total PSA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">quantitative hCG<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-15-3\">CA 15-3<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-27-29\">CA 27.29<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-a\">Inhibin A<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-b\">Inhibin B<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">LDH<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">immunofixation<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">free light chains<\/a> may be useful when symptoms, history, imaging, a confirmed diagnosis, or a specialist-defined question provides a reason to order them.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Monitoring Tests<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Serial tumor markers can be useful when a marker is validated for the cancer type and was informative for the individual. <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a> commonly support monitoring of marrow, kidney, liver, electrolyte, and metabolic effects of treatment. A marker trend should be interpreted with symptoms, examination, imaging, pathology, and the oncology plan.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Specialist-Directed Tests<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Tumor genomic profiling, plasma companion diagnostics, molecular residual-disease assays, complex hematologic testing, and some hereditary cancer panels require disease-specific selection and interpretation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Emerging or Insufficiently Validated Tests<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Multi-cancer detection tests remain an evolving category. Detecting a signal is not the same as proving that population use reduces cancer mortality or produces more benefit than harm. A positive result requires a coordinated diagnostic pathway, and a negative result does not replace established screening or symptom evaluation.<sup><a href=\"#ref-19\">19<\/a>, <a href=\"#ref-20\">20<\/a><\/sup><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Generally Not Appropriate for Broad Routine Screening<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In average-risk, asymptomatic people, broad bundles of CA-125, CEA, AFP, CA 19-9, hCG, LDH, CA 15-3, CA 27.29, inhibins, and similar markers are generally not supported as universal cancer screening. The chance of false-positive, incidental, or uninterpretable findings rises when many nonspecific tests are ordered without a defined pretest question.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Detailed Tests and Biomarkers<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Foundational and Selected Hematology Tests<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Test and quick facts<\/th><th>What it shows and how it is used<\/th><th>Preparation, influences, and limitations<\/th><\/tr><\/thead><tbody><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">Complete Blood Count with Differential and Platelets<\/a><br><strong>Aliases:<\/strong> CBC, CBC with differential<br><strong>Use status:<\/strong> Common or first-line; monitoring<\/th><td>Measures red-cell, white-cell, and platelet counts and indices. May evaluate anemia, infection or marrow patterns, establish a baseline, and monitor treatment effects.<\/td><td>Usually no fasting. Hydration, recent illness, steroids, treatment timing, altitude, pregnancy, and specimen quality may matter. It cannot identify the cause of an abnormal count or exclude cancer.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">Comprehensive Metabolic Panel<\/a><br><strong>Alias:<\/strong> CMP<br><strong>Use status:<\/strong> Common or first-line; monitoring<\/th><td>Measures selected kidney, liver, electrolyte, protein, calcium, and glucose values. May assess organ function, metabolic effects, and treatment safety.<\/td><td>Follow the order-specific fasting instructions. Hydration, medicines, supplements, illness, and hemolysis may affect results. It cannot establish a tumor's presence, location, type, or stage.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/urinalysis-ua-complete\">Complete Urinalysis<\/a><br><strong>Alias:<\/strong> UA<br><strong>Use status:<\/strong> Common or symptom-directed<\/th><td>Assesses urine blood, protein, glucose, cells, and other features. May help evaluate visible or microscopic blood in urine and alternative urinary causes.<\/td><td>Collection quality, menstruation, exercise, hydration, infection, stones, and medications can affect findings. Urinalysis cannot diagnose or exclude bladder, kidney, or prostate cancer.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">Lactate Dehydrogenase<\/a><br><strong>Aliases:<\/strong> LDH, LD<br><strong>Use status:<\/strong> Targeted; monitoring; specialist-directed<\/th><td>Measures an enzyme released with tissue and cell injury. May contribute to prognosis or monitoring in selected lymphomas, germ-cell tumors, and other defined settings.<\/td><td>Hemolysis, exercise, liver or muscle injury, infection, inflammation, and medicines may raise LDH. It does not identify cancer, site, or recurrence by itself.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">Serum Protein Electrophoresis<\/a><br><strong>Alias:<\/strong> SPEP<br><strong>Use status:<\/strong> Targeted; specialist-directed; monitoring<\/th><td>Shows the distribution of serum protein fractions and may reveal a monoclonal pattern. Used in selected evaluation of high total protein, anemia, kidney dysfunction, bone symptoms, or neuropathy.<\/td><td>Usually no fasting. Inflammation, liver disease, protein loss, immunoglobulin therapy, and specimen factors matter. It cannot diagnose multiple myeloma or another specific disorder alone.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">Serum Immunofixation<\/a><br><strong>Alias:<\/strong> IFE<br><strong>Use status:<\/strong> Targeted; specialist-directed; monitoring<\/th><td>Characterizes the type of monoclonal immunoglobulin or light chain when present and may follow an abnormal SPEP.<\/td><td>Recent monoclonal-antibody treatment, immunoglobulin administration, and method can affect interpretation. A detected monoclonal protein may occur in MGUS or other nonmalignant states.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">Kappa\/Lambda Free Light Chains with Ratio<\/a><br><strong>Aliases:<\/strong> FLC, sFLC<br><strong>Use status:<\/strong> Targeted; specialist-directed; monitoring<\/th><td>Measures free kappa and lambda light chains and their ratio. Complements SPEP and IFE in selected plasma-cell-disorder evaluation and monitoring.<\/td><td>Kidney function, inflammation, assay platform, and treatment matter. It cannot establish the exact disorder, organ involvement, or need for treatment by itself.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/beta-2-microglobulin-serum\">Beta-2 Microglobulin, Serum<\/a><br><strong>Alias:<\/strong> B2M<br><strong>Use status:<\/strong> Specialist-directed; prognostic or monitoring<\/th><td>Measures a small protein influenced by cell turnover and kidney filtration. May contribute to prognosis or monitoring in multiple myeloma, chronic lymphocytic leukemia, and some lymphomas.<\/td><td>Kidney dysfunction, inflammation, infection, and immune activation can raise it. It is not a cancer-screening or diagnostic test.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">Tumor-Marker Crosswalk<\/h3>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/06-tumor-marker-crosswalk-psa-ca125-cea-afp-ca19-9.webp?quality=100&amp;resize=1024%2C768&amp;ssl=1\" alt=\"Tumor-marker crosswalk showing PSA, CA-125, CEA, AFP, and CA 19-9 with their major uses and limitations.\"\/><figcaption class=\"wp-element-caption\">Traditional tumor markers have narrow, context-dependent roles. The crosswalk below adds the breast-cancer markers CA 15-3 and CA 27.29 and the specialist-directed ovarian markers Inhibin A and Inhibin B.<\/figcaption><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Marker and quick facts<\/th><th>What it shows and how it is used<\/th><th>Preparation, influences, and limitations<\/th><\/tr><\/thead><tbody><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA, Total<\/a><br><strong>Aliases:<\/strong> total PSA, prostate-specific antigen<br><strong>Use status:<\/strong> Risk-based or targeted; monitoring<\/th><td>May support individualized prostate-screening decisions, symptom evaluation, pretreatment baseline, and monitoring after diagnosis or treatment.<sup><a href=\"#ref-4\">4<\/a>, <a href=\"#ref-5\">5<\/a><\/sup><\/td><td>Benign enlargement, prostatitis, infection, ejaculation, procedures, urinary retention, and some medicines affect interpretation. No single value proves or excludes cancer.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">PSA, Free and Total<\/a><br><strong>Aliases:<\/strong> percent free PSA, free-to-total PSA ratio<br><strong>Use status:<\/strong> Targeted adjunct<\/th><td>May refine risk discussion in selected people with an elevated or borderline total PSA.<\/td><td>Interpret with total PSA, age, trend, prostate volume, examination, risk, and imaging. No percentage excludes clinically significant disease.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/post-prostatectomy-psa-test\">Post-Prostatectomy PSA<\/a><br><strong>Use status:<\/strong> Monitoring after prostatectomy<\/th><td>Uses a sensitive PSA method in the defined post-prostatectomy setting to follow the treating team's monitoring plan.<\/td><td>A single result should not be interpreted without timing, assay, prior values, pathology, and the oncology or urology plan.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a><br><strong>Aliases:<\/strong> cancer antigen 125, ovarian cancer antigen<br><strong>Use status:<\/strong> Targeted; monitoring<\/th><td>Most commonly monitors known ovarian cancer and may contribute to selected evaluation of a suspicious pelvic mass.<sup><a href=\"#ref-7\">7<\/a><\/sup><\/td><td>Menstruation, pregnancy, endometriosis, fibroids, pelvic inflammation, and liver disease may raise it. It is not routine screening for average-risk asymptomatic people.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-15-3\">CA 15-3<\/a><br><strong>Use status:<\/strong> Monitoring; specialist-directed<\/th><td>May help assess treatment response or recurrence in selected breast-cancer settings when informative for the individual.<sup><a href=\"#ref-2\">2<\/a><\/sup><\/td><td>Not a breast-cancer screening or diagnostic test. Benign conditions and other cancers may affect it; early disease may not raise it.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-27-29\">CA 27.29<\/a><br><strong>Use status:<\/strong> Monitoring; specialist-directed<\/th><td>May be followed in selected people with known breast cancer, particularly for metastatic or recurrence monitoring questions.<sup><a href=\"#ref-2\">2<\/a><\/sup><\/td><td>Does not replace mammography, diagnostic imaging, biopsy, pathology, or receptor testing. Interpret serially with the same method when possible.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">Carcinoembryonic Antigen<\/a><br><strong>Alias:<\/strong> CEA<br><strong>Use status:<\/strong> Monitoring<\/th><td>Commonly provides a baseline and supports treatment-response or recurrence monitoring in colorectal cancer and selected other cancers.<sup><a href=\"#ref-8\">8<\/a><\/sup><\/td><td>Smoking and several liver, digestive, inflammatory, and metabolic conditions may raise CEA. It is not a colorectal-cancer screening or diagnostic test.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">Alpha-Fetoprotein Tumor Marker<\/a><br><strong>Alias:<\/strong> AFP<br><strong>Use status:<\/strong> Targeted; monitoring<\/th><td>May contribute to selected liver-cancer and germ-cell-tumor evaluation, staging context, prognosis, and response monitoring.<sup><a href=\"#ref-2\">2<\/a>, <a href=\"#ref-9\">9<\/a><\/sup><\/td><td>Pregnancy and chronic liver disease materially affect interpretation. AFP may be elevated without cancer or normal despite cancer.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a><br><strong>Use status:<\/strong> Targeted; monitoring<\/th><td>May support treatment-response monitoring in pancreatic, biliary, gallbladder, gastric, and selected related cancers.<sup><a href=\"#ref-2\">2<\/a>, <a href=\"#ref-10\">10<\/a><\/sup><\/td><td>Biliary obstruction, cholangitis, pancreatitis, and other benign conditions can raise it. Some people do not produce CA 19-9. It is not population screening.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG, Total, Quantitative<\/a><br><strong>Aliases:<\/strong> beta-hCG, quantitative hCG<br><strong>Use status:<\/strong> Targeted; monitoring<\/th><td>May contribute to staging, prognosis, and monitoring in selected germ-cell and trophoblastic tumors.<sup><a href=\"#ref-2\">2<\/a><\/sup><\/td><td>Pregnancy is the central alternative explanation. Pituitary production, assay interference, and other rare causes may matter. It is not a universal screening marker.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-a\">Inhibin A<\/a><br><strong>Use status:<\/strong> Specialist-directed; monitoring<\/th><td>May be used with clinical findings and imaging in selected ovarian sex cord-stromal or granulosa-cell-tumor evaluation and follow-up.<sup><a href=\"#ref-15\">15<\/a><\/sup><\/td><td>Not a general ovarian-cancer screening test. Reproductive and menopausal status, tumor type, baseline result, and assay method matter.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-b\">Inhibin B<\/a><br><strong>Use status:<\/strong> Specialist-directed; monitoring<\/th><td>May be particularly useful in selected granulosa-cell-tumor follow-up when elevated or informative at diagnosis.<sup><a href=\"#ref-15\">15<\/a><\/sup><\/td><td>Not a stand-alone diagnostic or screening test. A normal result does not exclude disease, and performance varies by tumor and assay.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">An Elevated Tumor Marker Does Not Equal Cancer<\/h2>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/07-elevated-tumor-marker-does-not-equal-cancer.webp?quality=100&amp;resize=1024%2C576&amp;ssl=1\" alt=\"Six-step response to an elevated tumor marker: verify, clarify, review, compare, confirm, and follow up.\"\/><figcaption class=\"wp-element-caption\">A flagged tumor-marker result is a finding that needs context, not a diagnosis.<\/figcaption><\/figure>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Verify the exact test.<\/strong> Confirm the marker name, unit, laboratory interval, assay method, specimen, and whether the sample was hemolyzed or otherwise compromised.<\/li>\n\n\n\n<li><strong>Clarify the purpose.<\/strong> Screening, symptom evaluation, baseline measurement, treatment monitoring, and recurrence monitoring have different pretest probabilities and interpretations.<\/li>\n\n\n\n<li><strong>Review noncancer influences.<\/strong> Infection, inflammation, smoking, pregnancy, menstruation, prostate procedures, biliary obstruction, liver or kidney dysfunction, and medicines may matter depending on the marker.<\/li>\n\n\n\n<li><strong>Compare prior values and related results.<\/strong> A stable mild elevation may mean something different from a rapid, method-consistent rise. CBC, CMP, imaging, pathology, and treatment history can change the interpretation.<\/li>\n\n\n\n<li><strong>Repeat or confirm only when appropriate.<\/strong> A repeat result may be useful if the timing, preparation, sample quality, or transient illness could have affected the first test. Repetition should not delay urgent evaluation of symptoms.<\/li>\n\n\n\n<li><strong>Use clinician-directed follow-up.<\/strong> The next step may be observation, repeat testing, imaging, endoscopy, specialist referral, or biopsy. The marker itself does not choose the diagnosis.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\">Routine Cancer Screening Versus Tumor-Marker Use<\/h2>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/08-routine-cancer-screening-vs-tumor-marker-use.webp?quality=100&amp;resize=1024%2C576&amp;ssl=1\" alt=\"Comparison of guideline-based routine cancer screening with targeted tumor-marker use.\"\/><figcaption class=\"wp-element-caption\">Traditional tumor markers do not replace established screening tests, diagnostic imaging, endoscopy, biopsy, or pathology.<\/figcaption><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Cancer type<\/th><th>Screening or risk-directed pathway<\/th><th>What a tumor marker cannot replace<\/th><\/tr><\/thead><tbody><tr><th><strong>Breast cancer<\/strong><\/th><td>Use guideline-based mammography and any risk-directed imaging or genetic evaluation. Tumor-tissue biomarkers guide treatment after diagnosis.<sup><a href=\"#ref-22\">22<\/a><\/sup><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-15-3\">CA 15-3<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-27-29\">CA 27.29<\/a>, serum estrogen, and serum progesterone do not replace breast screening, diagnostic imaging, biopsy, or tissue receptor testing.<sup><a href=\"#ref-3\">3<\/a>, <a href=\"#ref-21\">21<\/a><\/sup><\/td><\/tr><tr><th><strong>Cervical cancer<\/strong><\/th><td>Use current cervical screening recommendations and appropriate diagnostic follow-up for an abnormal result.<sup><a href=\"#ref-23\">23<\/a><\/sup><\/td><td>There is no routine circulating tumor marker that substitutes for cervical screening.<\/td><\/tr><tr><th><strong>Colorectal cancer<\/strong><\/th><td>Use established stool-based tests, colonoscopy, or another guideline-recognized option. An FDA-approved blood-based screening test is available for defined average-risk adults; a positive result requires colonoscopy.<sup><a href=\"#ref-24\">24<\/a>, <a href=\"#ref-16\">16<\/a><\/sup><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a> is primarily a monitoring marker and is not a substitute for colorectal screening or diagnostic colonoscopy.<\/td><\/tr><tr><th><strong>Lung cancer<\/strong><\/th><td>Use low-dose CT for people who meet current eligibility criteria. Evaluate symptoms such as persistent cough or coughing blood promptly.<sup><a href=\"#ref-25\">25<\/a><\/sup><\/td><td>No routine blood tumor marker replaces low-dose CT or diagnostic chest imaging.<\/td><\/tr><tr><th><strong>Prostate cancer<\/strong><\/th><td>Consider <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> only through an informed, individualized decision that accounts for age, health, risk, preferences, potential follow-up, and possible harms.<sup><a href=\"#ref-4\">4<\/a>, <a href=\"#ref-5\">5<\/a><\/sup><\/td><td>PSA is not cancer-specific. A high value does not diagnose cancer, and a low value does not completely exclude it.<\/td><\/tr><tr><th><strong>Ovarian cancer<\/strong><\/th><td>Average-risk asymptomatic people should not use CA-125 as routine population screening. High-risk care requires individualized specialist guidance.<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-a\">Inhibin A<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-b\">Inhibin B<\/a> are not universal ovarian-cancer screening tests.<sup><a href=\"#ref-6\">6<\/a>, <a href=\"#ref-7\">7<\/a><\/sup><\/td><\/tr><tr><th><strong>Pancreatic cancer<\/strong><\/th><td>Average-risk asymptomatic adults should not undergo population screening. High-risk surveillance programs use specialist-defined protocols.<sup><a href=\"#ref-26\">26<\/a><\/sup><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a> cannot screen the general population or distinguish cancer from biliary obstruction or pancreatitis by itself.<\/td><\/tr><tr><th><strong>Liver cancer<\/strong><\/th><td>People at defined high risk may need specialist-directed surveillance using imaging and, in some protocols, AFP.<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a> alone cannot screen everyone, diagnose liver cancer, or exclude disease. Chronic liver disease and pregnancy can affect it.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Liquid Biopsy, ctDNA, MRD, and Multi-Cancer Detection Tests<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Liquid biopsy<\/em> is an umbrella term, not one test. Some assays analyze circulating tumor DNA or other material to select treatment for an already diagnosed cancer. Others assess molecular residual disease after treatment. A disease-specific blood screening test may have a defined regulatory indication. Multi-cancer detection assays ask a broader screening question and remain under active study.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Always identify the exact assay, intended population, regulatory status, specimen, cancer type, decision it is meant to support, and required follow-up. A result from one category should not be generalized to another.<sup><a href=\"#ref-17\">17<\/a>, <a href=\"#ref-18\">18<\/a>, <a href=\"#ref-19\">19<\/a><\/sup><\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/09-liquid-biopsy-ctdna-mrd-mced-evidence-1024x576.webp?quality=100&amp;resize=1024%2C576&amp;ssl=1\" alt=\"Comparison of liquid-biopsy uses including circulating tumor DNA, molecular residual disease, companion diagnostics, and multi-cancer detection.\"\/><figcaption class=\"wp-element-caption\">The evidence and regulatory status of liquid-biopsy assays depend on the exact test and intended use.<\/figcaption><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Assay category and status<\/th><th>Defined use<\/th><th>Critical limitation<\/th><\/tr><\/thead><tbody><tr><th><strong>Plasma companion diagnostic<\/strong><br><strong>Use status:<\/strong> FDA-authorized, treatment-specific<\/th><td>Looks for a defined alteration linked to a specific drug indication. FDA maintains a list of authorized companion diagnostic devices.<sup><a href=\"#ref-17\">17<\/a><\/sup><\/td><td>Use is limited to the assay, cancer type, specimen, and treatment described in the authorization or labeling. It is not general cancer screening.<\/td><\/tr><tr><th><strong>Molecular residual-disease assay<\/strong><br><strong>Use status:<\/strong> Disease-specific and rapidly evolving<\/th><td>Looks for a molecular signal after treatment. In May 2026, FDA approved Signatera CDx as a companion diagnostic in a defined post-cystectomy muscle-invasive bladder-cancer setting for adjuvant atezolizumab selection.<sup><a href=\"#ref-18\">18<\/a><\/sup><\/td><td>That approval does not establish the same role for every MRD assay, cancer, treatment, or surveillance schedule. A negative result is not a universal all-clear.<\/td><\/tr><tr><th><strong>Disease-specific blood screening<\/strong><br><strong>Use status:<\/strong> FDA-approved for a defined population<\/th><td>The Shield blood test is approved for colorectal-cancer screening in average-risk adults age 45 or older. A positive result should be followed by colonoscopy.<sup><a href=\"#ref-16\">16<\/a><\/sup><\/td><td>It is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk people. A screening option must be chosen with attention to performance, adherence, and required follow-up.<\/td><\/tr><tr><th><strong>Multi-cancer detection test<\/strong><br><strong>Use status:<\/strong> Emerging or research-oriented for population outcomes<\/th><td>Analyzes one or more signals to look for multiple cancers. NCI notes that definitive evidence of reduced overall cancer mortality is not yet available, and benefits and harms remain under study.<sup><a href=\"#ref-19\">19<\/a><\/sup><\/td><td>A positive signal starts a diagnostic process rather than establishing cancer. A negative result does not replace proven screening. The NHS-Galleri trial did not meet its primary endpoint of reducing late-stage diagnoses, although other stage-distribution findings continue to be studied.<sup><a href=\"#ref-20\">20<\/a><\/sup><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">A Patient-Centered Test-Selection Framework<\/h2>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/13-cancer-diagnostic-pathway-blood-test-imaging-biopsy.webp?quality=100&amp;resize=1024%2C576&amp;ssl=1\" alt=\"Cancer diagnostic pathway moving from symptoms and risk to blood testing, imaging or endoscopy, biopsy, pathology, and a follow-up plan.\"\/><figcaption class=\"wp-element-caption\">Blood testing is one part of a broader diagnostic pathway that may require imaging, endoscopy, biopsy, pathology, and specialist review.<\/figcaption><\/figure>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Define the question before ordering.<\/strong> Is the goal screening, symptom evaluation, baseline measurement, treatment safety, response monitoring, recurrence monitoring, or hereditary-risk assessment?<\/li>\n\n\n\n<li><strong>Estimate pretest probability.<\/strong> Symptoms, age, family history, exposures, examination, prior cancer, and imaging findings change the meaning of the same result.<\/li>\n\n\n\n<li><strong>Select the narrowest evidence-based test.<\/strong> Avoid adding unrelated markers simply because they are available in a large panel.<\/li>\n\n\n\n<li><strong>Check whether the test is validated for that purpose.<\/strong> A marker used to monitor known disease may perform poorly as screening in people without symptoms.<\/li>\n\n\n\n<li><strong>Plan preparation and timing.<\/strong> Consider fasting instructions, treatment cycles, recent procedures, smoking, exercise, illness, reproductive status, and medications.<\/li>\n\n\n\n<li><strong>Plan the response to each possible result.<\/strong> Before testing, know what a positive, negative, indeterminate, or discordant result would change.<\/li>\n\n\n\n<li><strong>Preserve comparability when trending.<\/strong> Use the same laboratory and method when possible, especially for serial tumor markers or sensitive PSA monitoring.<\/li>\n\n\n\n<li><strong>Confirm rather than overinterpret.<\/strong> Repeat testing, imaging, endoscopy, pathology, or specialist review may be necessary.<\/li>\n\n\n\n<li><strong>Do not delay urgent evaluation.<\/strong> Severe bleeding, fever during treatment, jaundice with systemic illness, neurologic deficits, urinary retention, or rapidly worsening symptoms require prompt care.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\">Individual Test Versus Focused Panel Versus Broad Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Order type<\/th><th>When it may fit<\/th><th>Main limitation<\/th><\/tr><\/thead><tbody><tr><th><strong>Individual test<\/strong><\/th><td>Best when one defined question points to one marker or one foundational test.<\/td><td>Usually easier to interpret and less likely to generate unrelated abnormalities, but may be incomplete if the clinical question requires a coordinated set of tests.<\/td><\/tr><tr><th><strong>Focused panel or profile<\/strong><\/th><td>Best when several complementary measurements answer one clinical question, such as CBC indices or protein studies.<\/td><td>Panel contents must be reviewed. A coherent panel is not automatically a cancer-screening panel.<\/td><\/tr><tr><th><strong>Broad multi-marker panel<\/strong><\/th><td>May be appropriate only in a defined specialist or research context with a planned follow-up pathway.<\/td><td>In average-risk asymptomatic people, many nonspecific markers can increase false positives, incidental findings, anxiety, and unnecessary procedures without proven benefit.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Preparation, Timing, and Common Interferences<\/h2>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/10-tumor-marker-test-preparation-interferences.webp?quality=100&amp;resize=1024%2C576&amp;ssl=1\" alt=\"Preparation and interference checklist for tumor-marker testing, including timing, medicines, smoking, reproductive status, procedures, and specimen quality.\"\/><figcaption class=\"wp-element-caption\">Preparation and context matter because many tumor markers are influenced by noncancerous conditions, treatment timing, procedures, or specimen factors.<\/figcaption><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Test or test group<\/th><th>Preparation and timing<\/th><th>Influences and limitations<\/th><\/tr><\/thead><tbody><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, and treatment-safety testing<\/th><td>Follow the specific order instructions. Fasting may be requested when glucose or other fasting-sensitive tests are included. Keep hydration and treatment-cycle timing consistent when possible.<\/td><td>Dehydration, infection, steroids, treatment timing, supplements, medicines, and specimen hemolysis may change results. Do not stop medicines without professional instruction.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free PSA<\/a><\/th><td>Document recent prostate infection, urinary retention, procedures, biopsy, catheterization, ejaculation, and relevant medicines. Follow the ordering clinician's timing instructions.<\/td><td>A temporary rise may reflect a noncancer prostate influence. A repeat may be appropriate, but persistent symptoms or concerning examination findings still need evaluation.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a><\/th><td>Usually no fasting. Record smoking status and relevant liver, digestive, inflammatory, or metabolic conditions.<\/td><td>Smoking and noncancerous disease may raise the result. The same assay is preferable for serial comparison.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-a\">Inhibin A<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-b\">Inhibin B<\/a><\/th><td>Document pregnancy possibility, menstrual or menopausal status, pelvic conditions, surgery, and the exact reason for testing.<\/td><td>Reproductive physiology and benign pelvic or liver conditions can affect interpretation. These tests do not replace pelvic imaging or pathology.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">quantitative hCG<\/a><\/th><td>Document pregnancy status and relevant liver or germ-cell-tumor history. Use the same method for serial monitoring when possible.<\/td><td>Pregnancy is a major confounder. Chronic liver disease can raise AFP. Assay interference and clinical context may matter for hCG.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a><\/th><td>Document jaundice, biliary obstruction, cholangitis, pancreatitis, and recent procedures or treatment.<\/td><td>Obstruction and inflammation can cause marked elevations, and some people do not produce CA 19-9.<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">immunofixation<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">free light chains<\/a><\/th><td>Usually no fasting. Provide kidney function, inflammatory status, recent immunoglobulin administration, and monoclonal-antibody treatment history.<\/td><td>Kidney dysfunction and inflammation may alter free-light-chain concentrations. Therapy can create patterns that complicate electrophoresis or immunofixation.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">How to Read Cancer-Related Laboratory Results<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Use <a href=\"https:\/\/www.ultalabtests.com\/blog\/lab-testing-knowledge-center\/how-to-read-lab-results\/\">How to Read and Understand Your Lab Results<\/a> for a fuller explanation of reference intervals, decision thresholds, flags, units, biological variation, analytical variation, repeat testing, and trends.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Report term<\/th><th>What it means<\/th><th>What it does not mean<\/th><\/tr><\/thead><tbody><tr><th><strong>Reference interval<\/strong><\/th><td>The range or decision information supplied by the performing laboratory for that method and population.<\/td><td>It is not a universal boundary between cancer and no cancer.<\/td><\/tr><tr><th><strong>Flag<\/strong><\/th><td>A notation that a value is outside the laboratory interval or decision limit.<\/td><td>A high or low flag does not identify the cause or determine urgency by itself.<\/td><\/tr><tr><th><strong>Unit and method<\/strong><\/th><td>The measurement unit and assay platform used by the laboratory.<\/td><td>Results from different methods may not be directly interchangeable.<\/td><\/tr><tr><th><strong>Baseline<\/strong><\/th><td>A result obtained before treatment or before serial monitoring begins.<\/td><td>A marker that was never elevated may not be useful for monitoring that individual.<\/td><\/tr><tr><th><strong>Trend<\/strong><\/th><td>The direction and magnitude of change across comparable measurements.<\/td><td>A trend must be interpreted with timing, treatment, symptoms, imaging, and biological and analytical variation.<\/td><\/tr><tr><th><strong>Discordant result<\/strong><\/th><td>A laboratory result that does not fit symptoms, imaging, pathology, or the rest of the data.<\/td><td>Discordance is a reason to verify the test and context, not to ignore either the laboratory result or the clinical picture.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Fictional Tumor-Marker Report Walkthrough<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Educational example only:<\/strong> The patient, values, and circumstances below are fictional. No universal reference interval is implied.<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/11-how-to-read-tumor-marker-lab-report.webp?quality=100&amp;resize=1024%2C768&amp;ssl=1\" alt=\"Educational diagram showing how to read a tumor-marker laboratory report, including test name, value, unit, flag, interval, prior result, and clinical context.\"\/><figcaption class=\"wp-element-caption\">A report should be read by verifying the exact test, unit, method, interval, indication, prior values, and related findings.<\/figcaption><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Report element<\/th><th>Fictional entry or question<\/th><th>Interpretation limit<\/th><\/tr><\/thead><tbody><tr><th><strong>Test<\/strong><br><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a><\/th><td>Was it ordered to monitor a known CEA-producing cancer or as unspecific screening?<\/td><td>The indication determines the pretest probability and the appropriate next step.<\/td><\/tr><tr><th><strong>Value and unit<\/strong><br>Mildly above the laboratory interval in ng\/mL<\/th><td>What exact method and interval were used? Was the same assay used previously?<\/td><td>A mild elevation is not a diagnosis.<\/td><\/tr><tr><th><strong>Flag<\/strong><br>H<\/th><td>The result is above the laboratory interval.<\/td><td>The flag does not identify cancer or the cause of the elevation.<\/td><\/tr><tr><th><strong>Prior result<\/strong><br>No prior CEA available<\/th><td>Without a baseline, a trend cannot be assessed.<\/td><td>One value cannot show whether the marker is rising, stable, or falling.<\/td><\/tr><tr><th><strong>Related results<\/strong><br><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a> without a major abnormality; mild liver-enzyme elevation on <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a><\/th><td>Could liver, digestive, inflammatory, metabolic, medication, or smoking factors contribute?<\/td><td>Normal related tests do not exclude cancer, and abnormal related tests do not prove it.<\/td><\/tr><tr><th><strong>History and preparation<\/strong><br>Smoking status, recent illness, and reason for ordering not documented<\/th><td>These missing details materially limit interpretation.<\/td><td>A result should not be interpreted without the clinical context that could explain it.<\/td><\/tr><tr><th><strong>Possible follow-up<\/strong><\/th><td>Review indication and symptoms, assess benign contributors, confirm only when appropriate, and use guideline-based colorectal screening or targeted diagnostic evaluation.<\/td><td>CEA should not be used to diagnose or exclude colorectal cancer.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">When Not to Order a Tumor Marker as a Stand-Alone Test<\/h2>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/12-when-not-to-order-tumor-marker-tests.webp?quality=100&amp;resize=1024%2C576&amp;ssl=1\" alt=\"Situations when broad or stand-alone tumor-marker testing is unlikely to help, including average-risk screening and replacing symptom evaluation.\"\/><figcaption class=\"wp-element-caption\">A tumor marker should answer a defined question rather than serve as a broad reassurance test.<\/figcaption><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Do not use a traditional tumor marker to reassure yourself that persistent symptoms are not cancer.<\/li>\n\n\n\n<li>Do not replace established screening with a marker that was designed mainly for monitoring known disease.<\/li>\n\n\n\n<li>Do not order a broad multi-marker panel without deciding in advance how each possible abnormal result will be evaluated.<\/li>\n\n\n\n<li>Do not compare serial values from different methods or laboratories as though they are always interchangeable.<\/li>\n\n\n\n<li>Do not assume that a marker is useful for monitoring when it was never elevated or informative before treatment.<\/li>\n\n\n\n<li>Do not use serum estrogen or progesterone to determine breast-cancer receptor status.<\/li>\n\n\n\n<li>Do not interpret CA 15-3, CA 27.29, Inhibin A, or Inhibin B as general early-detection tests.<\/li>\n\n\n\n<li>Do not delay imaging, endoscopy, biopsy, or urgent care while waiting for a tumor-marker result.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Repeat and Confirmatory Testing<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Repeat testing can be useful when a specimen problem, acute illness, procedure, timing issue, medication, or known biological variation could explain an unexpected result. The repeat should generally use the same method and laboratory when a trend is the goal. The reason for the repeat, timing, and action threshold should be clear.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Confirmatory testing means more than drawing the same marker again. Depending on the question, confirmation may require a different laboratory method, imaging, endoscopy, pathology, tumor-tissue biomarker testing, bone-marrow evaluation, or specialist assessment. Repeating a marker indefinitely without a defined plan can prolong uncertainty without answering the clinical question.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">When Professional or Urgent Care Matters<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Seek prompt professional evaluation for a new mass, persistent unexplained bleeding, progressive jaundice, blood in urine, worsening neurologic symptoms, unexplained weight loss, persistent focal pain, or symptoms that do not resolve. Contact the oncology team promptly for fever during treatment, rapidly worsening weakness, new bleeding, severe vomiting, dehydration, or unexpected treatment-related symptoms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Emergency evaluation may be necessary for uncontrolled bleeding, fainting, severe shortness of breath, coughing or vomiting blood, black tarry stool, urinary retention with severe pain or fever, jaundice with confusion or fever, new weakness or loss of bladder or bowel control, or other rapidly progressive symptoms. A laboratory order should never delay emergency care.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Explore Related Cancer and Laboratory Guides<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/prostate-cancer\/psa-levels-explained\/\">PSA Levels Explained<\/a> for total PSA, free PSA, trends, limitations, and follow-up questions.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/prostate-cancer\/prostate-cancer-symptoms-detection\/\">Prostate Cancer Symptoms and Detection<\/a> for symptom-focused evaluation and the role of PSA, imaging, and biopsy.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/breast-cancer\/how-can-i-reduce-my-breast-cancer-risk\/\">How Can I Reduce My Breast Cancer Risk?<\/a> for risk assessment and established screening.<\/li>\n\n\n\n<li><a href=\"#hormone-sensitive-cancers\">Hormone-sensitive cancers: receptor testing, blood hormones, and tumor markers<\/a> for the incorporated explanation of tissue receptors, CA 15-3, CA 27.29, and inhibins.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/key-symptoms-of-pancreatic-cancer-to-watch-for\/\">Key Symptoms of Pancreatic Cancer<\/a> for symptom evaluation and why CA 19-9 is not a general screening test.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/bladder-cancer-the-5-warning-signs\/\">Bladder Cancer Warning Signs<\/a> for blood in urine and the need for urologic evaluation.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/thyroid\/thyroid-cancer\/six-common-thyroid-cancer-symptoms\/\">Common Thyroid Cancer Symptoms<\/a> for thyroid nodules, symptoms, imaging, and biopsy context.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/genomic-testing\/genetic-genomic-testing\/\">Genetic and Genomic Testing<\/a> for hereditary-risk testing, tumor genomic testing, and pharmacogenomics.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/blood-disorders\/cbc-anemia-blood-tests\/\">CBC and Anemia Blood Tests<\/a> for anemia and blood-cell follow-up.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/inflammation\/inflammation-autoimmune-blood-tests\/\">Inflammation and Autoimmune Blood Tests<\/a> for inflammatory patterns that can influence nonspecific laboratory findings.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Cancer-Related Tests Discussed in This Guide<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The following links lead to individual Ulta Lab Tests pages. Availability and suitability depend on the purpose of testing. A direct-access order does not diagnose cancer or replace established screening, imaging, pathology, or oncology care.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Foundational and Symptom-Directed Tests<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">Complete Blood Count with Differential and Platelets<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">Comprehensive Metabolic Panel<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/urinalysis-ua-complete\">Complete Urinalysis<\/a><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Prostate-Related Tests<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA, Total<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">PSA, Free and Total<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/post-prostatectomy-psa-test\">Post-Prostatectomy PSA<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/testosterone-total-ms\">Testosterone, Total, Mass Spectrometry<\/a> when specifically directed as part of an endocrine-treatment monitoring plan<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Selected Tumor Markers<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">Alpha-Fetoprotein Tumor Marker<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG, Total, Quantitative<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-15-3\">CA 15-3<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-27-29\">CA 27.29<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-a\">Inhibin A<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/inhibin-b\">Inhibin B<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">Lactate Dehydrogenase<\/a><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Protein and Plasma-Cell Studies<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">Serum Protein Electrophoresis<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">Serum Immunofixation<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">Kappa\/Lambda Free Light Chains with Ratio<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/beta-2-microglobulin-serum\">Beta-2 Microglobulin, Serum<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Browse the <a href=\"https:\/\/www.ultalabtests.com\/testing\/categories\/cancer-screening\/tumor-marker\">Ulta Lab Tests tumor-marker category<\/a> only after defining the purpose of testing. A larger panel is not automatically a better screening strategy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How Ulta Lab Tests May Fit Into the Process<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ulta Lab Tests provides access to many of the individual laboratory tests discussed in this guide. Direct-access testing can make it easier to obtain a defined baseline or follow a clinician-directed plan, but ordering access does not change a test's medical limitations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Before ordering, confirm the purpose, preparation, timing, and follow-up plan. Review <a href=\"https:\/\/www.ultalabtests.com\/blog\/lab-testing-knowledge-center\/direct-access-lab-testing\/\">Direct-Access Lab Testing: How It Works and What to Expect<\/a> for the ordering and collection process, and use <a href=\"https:\/\/www.ultalabtests.com\/blog\/lab-testing-knowledge-center\/how-to-read-lab-results\/\">How to Read and Understand Your Lab Results<\/a> when reviewing the report. Persistent symptoms, marked abnormalities, or cancer-treatment decisions require qualified professional care.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Questions to Ask Before or After Testing<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Is this test being used for screening, symptom evaluation, baseline measurement, treatment safety, response monitoring, or recurrence monitoring?<\/li>\n\n\n\n<li>Is the marker validated for my cancer type and intended use?<\/li>\n\n\n\n<li>Was the marker elevated or otherwise informative before treatment?<\/li>\n\n\n\n<li>Could a noncancerous condition, recent procedure, medicine, smoking, pregnancy, menstruation, infection, or specimen issue affect the result?<\/li>\n\n\n\n<li>Should serial results use the same laboratory and method?<\/li>\n\n\n\n<li>What result would change the next step?<\/li>\n\n\n\n<li>Would a positive result lead to repeat testing, imaging, endoscopy, biopsy, or specialist referral?<\/li>\n\n\n\n<li>What does a negative result fail to exclude?<\/li>\n\n\n\n<li>Am I replacing an established screening test with a less-proven blood test?<\/li>\n\n\n\n<li>Which symptoms or changes require urgent care rather than another laboratory test?<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Can a blood test diagnose cancer?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Usually not by itself. Blood tests may reveal patterns, measure selected tumor markers, or identify a molecular signal, but most cancer diagnoses require imaging, endoscopy, biopsy, pathology, or another disease-specific confirmation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Does a normal tumor marker rule out cancer?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. Some cancers do not produce the marker, early disease may produce little of it, and individual biology varies. Persistent symptoms or an abnormal examination or imaging finding still require evaluation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Does a high tumor marker mean I have cancer?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. Benign conditions can raise many markers. The test, unit, method, reason for ordering, prior values, symptoms, and related findings must be reviewed before choosing follow-up.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Which markers are most often used for monitoring?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Examples include PSA in prostate cancer, CEA in colorectal cancer, CA-125 in ovarian cancer, AFP and hCG in selected germ-cell tumors, CA 19-9 in selected pancreaticobiliary cancers, CA 15-3 or CA 27.29 in selected breast-cancer settings, and Inhibin A or Inhibin B in selected ovarian sex cord-stromal tumors. The exact role depends on the cancer, baseline result, treatment, and guideline or specialist plan.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Is PSA a prostate-cancer test?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">PSA is prostate-associated, not cancer-specific. It may support an informed screening decision, evaluation of selected prostate concerns, or monitoring after diagnosis or treatment. Benign enlargement, inflammation, infection, procedures, and medicines may affect the result.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Can CA-125 screen for ovarian cancer?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">It is not recommended as routine population screening for average-risk asymptomatic people. It is used mainly to monitor known ovarian cancer and may contribute to evaluation of a suspicious pelvic mass or a specialist-directed high-risk plan.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Can estrogen or progesterone blood tests identify a hormone-sensitive cancer?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. A blood hormone concentration does not determine whether a tumor contains estrogen or progesterone receptors. In breast cancer, receptor status is generally tested directly on tumor tissue obtained during biopsy or surgery. Serum hormone testing may have selected endocrine or treatment-monitoring uses, but it does not replace screening, diagnostic imaging, biopsy, or tumor-tissue biomarker testing.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Can CA 15-3 or CA 27.29 detect breast cancer early?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">They should not be used as stand-alone early-detection or screening tests. They may support monitoring in selected people with known breast cancer, particularly advanced disease, when the marker is informative for that individual.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What are Inhibin A and Inhibin B used for?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">They may aid specialist-directed evaluation or monitoring of selected ovarian sex cord-stromal tumors, including granulosa-cell tumors. They are not general ovarian-cancer screening tests, and interpretation depends on reproductive status, tumor biology, baseline values, assay method, imaging, and pathology.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Why are CBC and CMP included in cancer-related testing?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">They assess blood-cell and organ-function patterns that may support symptom evaluation, establish baselines, and monitor treatment safety. They are nonspecific and cannot locate or diagnose a tumor.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Is every liquid biopsy a cancer-screening test?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. Some liquid biopsies are companion diagnostics for treatment selection, some assess molecular residual disease, some have a defined disease-specific screening indication, and others are emerging multi-cancer detection tests. The exact assay and intended use must be checked.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Have multi-cancer detection tests been proven to save lives?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Definitive evidence that population use reduces overall cancer mortality is not yet available. Trials are evaluating benefits, harms, stage distribution, diagnostic workups, and mortality. These tests do not replace established screening.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How is hereditary cancer testing different from a tumor marker?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Hereditary testing looks for germline variants that may affect inherited risk and relatives. Tumor-marker testing usually measures a circulating protein or disease signal. Tumor genomic testing examines acquired changes in cancer cells and may guide treatment. These tests answer different questions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Should I order the largest cancer panel available?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Not automatically. Larger panels can generate incidental abnormalities, false reassurance, anxiety, and follow-up procedures without improving screening. A focused test linked to a defined clinical question is usually easier to interpret.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Conclusion: Use Cancer Blood Tests for the Right Question<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Cancer blood tests include routine blood counts and chemistry testing, selected tumor markers, monoclonal-protein studies, and increasingly specialized molecular assays. Focused testing can support risk discussions, diagnostic evaluation, treatment safety, response assessment, and recurrence monitoring. It cannot by itself diagnose most cancers, rule cancer out, or replace established screening, imaging, endoscopy, biopsy, pathology, and specialist evaluation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The safest approach begins with the purpose of testing, weighs false-positive and false-negative consequences, and interprets each result in the context of symptoms, risk, preparation, method, related findings, and trends. For hormone-sensitive cancers, keep tissue receptor testing, circulating hormone measurements, and traditional tumor markers conceptually separate. CA 15-3, CA 27.29, Inhibin A, and Inhibin B have selected monitoring roles; they are not stand-alone early-detection tests.<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/14-cancer-blood-tests-key-takeaways-next-steps.webp?quality=100&amp;resize=1024%2C576&amp;ssl=1\" alt=\"Key takeaways and next steps for cancer blood tests and tumor markers.\"\/><figcaption class=\"wp-element-caption\">Use cancer blood tests to answer a defined question, preserve method-consistent trends, and confirm concerning findings through the appropriate diagnostic pathway.<\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">References<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>National Cancer Institute. <a href=\"https:\/\/www.cancer.gov\/about-cancer\/diagnosis-staging\/diagnosis\/tumor-markers-fact-sheet\">Tumor Markers<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>National Cancer Institute. <a href=\"https:\/\/www.cancer.gov\/about-cancer\/diagnosis-staging\/diagnosis\/tumor-markers-list\">Tumor Marker Tests in Common Use<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>National Cancer Institute. <a href=\"https:\/\/www.cancer.gov\/types\/breast\/diagnosis\/breast-cancer-biomarker-tests\">Tests for Breast Cancer Biomarkers<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>National Cancer Institute. <a href=\"https:\/\/www.cancer.gov\/types\/prostate\/psa-fact-sheet\">Prostate-Specific Antigen (PSA) Test<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>U.S. Preventive Services Task Force. <a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/prostate-cancer-screening\">Prostate Cancer: Screening<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>U.S. Preventive Services Task Force. <a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/ovarian-cancer-screening\">Ovarian Cancer: Screening<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>MedlinePlus. <a href=\"https:\/\/medlineplus.gov\/lab-tests\/ca-125-blood-test-ovarian-cancer\/\">CA-125 Blood Test (Ovarian Cancer)<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>MedlinePlus. <a href=\"https:\/\/medlineplus.gov\/lab-tests\/cea-test\/\">CEA Test<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>MedlinePlus. <a href=\"https:\/\/medlineplus.gov\/lab-tests\/alpha-fetoprotein-afp-tumor-marker-test\/\">Alpha Fetoprotein (AFP) Tumor Marker Test<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>MedlinePlus. <a href=\"https:\/\/medlineplus.gov\/lab-tests\/ca-19-9-blood-test-pancreatic-cancer\/\">CA 19-9 Blood Test (Pancreatic Cancer)<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>MedlinePlus. <a href=\"https:\/\/medlineplus.gov\/lab-tests\/complete-blood-count-cbc\/\">Complete Blood Count (CBC)<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>MedlinePlus. <a href=\"https:\/\/medlineplus.gov\/lab-tests\/comprehensive-metabolic-panel-cmp\/\">Comprehensive Metabolic Panel (CMP)<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>MedlinePlus. <a href=\"https:\/\/medlineplus.gov\/lab-tests\/protein-electrophoresis-by-immunofixation-blood-test\/\">Protein Electrophoresis by Immunofixation Blood Test<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>MedlinePlus. <a href=\"https:\/\/medlineplus.gov\/lab-tests\/free-light-chains\/\">Free Light Chains<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>Mom CH, Engelen MJA, Willemse PHB, et al. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17306349\/\">Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>U.S. Food and Drug Administration. <a href=\"https:\/\/www.fda.gov\/medical-devices\/recently-approved-devices\/shield-p230009\">Shield - P230009<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>U.S. Food and Drug Administration. <a href=\"https:\/\/www.fda.gov\/medical-devices\/in-vitro-diagnostics\/list-fda-authorized-companion-diagnostic-devices-in-vitro-and-imaging-tools\">List of FDA-Authorized Companion Diagnostic Devices<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>U.S. Food and Drug Administration. <a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-adjuvant-treatment-muscle-invasive-bladder-cancer-patients-molecular\">FDA Approves Atezolizumab for Adjuvant Treatment of Muscle-Invasive Bladder Cancer in Patients with Molecular Residual Disease<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>National Cancer Institute, Division of Cancer Prevention. <a href=\"https:\/\/prevention.cancer.gov\/research-areas\/networks-consortia-programs\/csrn\/q-a-about-mcd-tests\">Questions and Answers About Multi-Cancer Detection Tests<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>NHS-Galleri Trial. <a href=\"https:\/\/www.nhs-galleri.org\/what-the-trial-found\">What the Trial Found<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>National Cancer Institute. <a href=\"https:\/\/www.cancer.gov\/types\/breast\/treatment\/hormone-therapy\">Hormone Therapy for Breast Cancer<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>U.S. Preventive Services Task Force. <a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/breast-cancer-screening\">Breast Cancer: Screening<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>U.S. Preventive Services Task Force. <a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/cervical-cancer-screening\">Cervical Cancer: Screening<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>U.S. Preventive Services Task Force. <a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/colorectal-cancer-screening\">Colorectal Cancer: Screening<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>U.S. Preventive Services Task Force. <a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/lung-cancer-screening\">Lung Cancer: Screening<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>U.S. Preventive Services Task Force. <a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/pancreatic-cancer-screening\">Pancreatic Cancer: Screening<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li>MedlinePlus. <a href=\"https:\/\/medlineplus.gov\/lab-tests\/beta-2-microglobulin-b2m-tumor-marker-test\/\">Beta 2 Microglobulin (B2M) Tumor Marker Test<\/a>. Accessed August 11, 2026.<\/li>\n\n\n\n<li><\/li>\n<\/ol>\n\n\n\n<h2 id=\"h-editorial-disclosure-authorship-and-medical-note\" class=\"wp-block-heading\"><strong>Editorial Disclosure, Authorship, and Medical Note<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ulta Lab Tests offers laboratory-testing services and links to individual tests discussed on this page. This educational content does not provide an individual diagnosis or treatment plan. Cancer screening, diagnostic evaluation, treatment, and surveillance should follow current guidelines and the plan established with qualified health professionals.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Written by:<\/strong> John R. | <strong>Originally published:<\/strong> August 1, 2026 | <strong>Last updated:<\/strong> August 11, 2026<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Medical note:<\/strong> This guide is educational. A clinician should select and interpret testing in the context of symptoms, diagnoses, medications, pregnancy status, nutrition, hydration, and prior results. Do not start, stop, or change a prescription based on this article or one laboratory result.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cancer blood tests include routine blood counts and chemistry tests, selected tumor markers, protein studies, and specialized molecular assays. They can support risk discussions, symptom evaluation, pretreatment baselines, treatment-safety monitoring, response assessment, and follow-up. However, [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":3349,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[74,281,63,62,69,64,75,70,4981,4980,210,66,72,241,67,73,203],"tags":[5539,5538,5543,5558,5547,5553,5549,1357,5582,5534,5537,5541,5586,5573,5574,5535,5545,1367,2662,5575,5542,5533,5531,1470,5550,5578,2085,5536,1337,2080,5587,2436,5546,5551,5540,5563,2700,5569,5552,5568,5579,5577,5565,5562,5570,5572,5548,5571,5580,5584,5560,5585,5564,5544,5583,5556,5529,5530,5555,5554,2692,5561,3562,1507,1505,5432,5559,5567,5576,5557,2694,5566,5532,5581,1349],"class_list":["post-2994","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breast-cancer","category-breast-health","category-all-cancer","category-cancer","category-cancer-and-tumor-markers-men","category-cancer-and-tumor-markers-women","category-cervical-cancer","category-colon-and-rectal-cancer","category-lab-testing-knowledge-center-lab-testing-knowledge-center","category-lab-testing-knowledge-center","category-mens-health","category-ovarian-cancer","category-pancreatic-cancer","category-prostate","category-prostate-cancer","category-testicular-cancer","category-womens-health","tag-abnormal-cancer-marker","tag-afp-test","tag-alpha-fetoprotein","tag-beta-2-microglobulin","tag-blood-tests-for-cancer","tag-ca-19-9-test","tag-ca-125-test-2","tag-cancer-biomarkers","tag-cancer-blood-test-results","tag-cancer-blood-tests","tag-cancer-diagnostic-support","tag-cancer-follow-up-testing","tag-cancer-genomics","tag-cancer-lab-test-preparation","tag-cancer-marker-interpretation","tag-cancer-monitoring-tests","tag-cancer-recurrence-monitoring","tag-cancer-risk-assessment","tag-cancer-screening-blood-tests","tag-cancer-screening-guidelines","tag-cancer-screening-limitations","tag-cancer-treatment-monitoring","tag-carcinoembryonic-antigen","tag-cbc-test","tag-cea-test","tag-circulating-tumor-dna","tag-cmp-test","tag-colorectal-cancer-monitoring","tag-complete-blood-count","tag-comprehensive-metabolic-panel","tag-ctdna","tag-direct-access-lab-testing-2","tag-elevated-tumor-marker","tag-false-negative-tumor-marker","tag-false-positive-tumor-marker","tag-free-light-chains","tag-free-psa","tag-genetic-cancer-risk","tag-germ-cell-tumor-markers","tag-hcg-tumor-marker","tag-hereditary-cancer-testing","tag-imaging-and-biopsy","tag-kappa-lambda-ratio","tag-lactate-dehydrogenase","tag-ldh-test","tag-liquid-biopsy","tag-liver-cancer-tumor-marker","tag-lymphoma-monitoring","tag-mced-tests","tag-molecular-residual-disease","tag-monoclonal-gammopathy","tag-multi-cancer-early-detection","tag-multiple-myeloma-testing","tag-noncancer-causes-of-elevated-tumor-markers","tag-oncology-lab-tests","tag-organ-function-testing","tag-ovarian-cancer-monitoring","tag-ovarian-cancer-tumor-marker","tag-pancreatic-cancer-monitoring","tag-pancreatic-cancer-tumor-marker","tag-percent-free-psa","tag-plasma-cell-disorder-testing","tag-prostate-cancer-monitoring","tag-prostate-cancer-screening","tag-psa-test","tag-quantitative-hcg","tag-serum-immunofixation","tag-serum-protein-electrophoresis","tag-specialist-directed-testing","tag-spep-test","tag-total-psa","tag-treatment-safety-testing","tag-tumor-marker-tests","tag-tumor-marker-trends","tag-tumor-markers"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.7 (Yoast SEO v28.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps | Ulta Lab Tests<\/title>\n<meta name=\"description\" content=\"Cancer blood tests and tumor marker tests explained: learn why cancer screening blood tests have limits and how results guide follow-up care.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps\" \/>\n<meta property=\"og:description\" content=\"Cancer blood tests and tumor marker tests explained: learn why cancer screening blood tests have limits and how results guide follow-up care.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/\" \/>\n<meta property=\"og:site_name\" content=\"Ulta Lab Tests\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/ultalabtests\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-11T18:39:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-12T04:33:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/02-cancer-blood-tests-tumor-markers-square-hero.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"John R\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"John R\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"40 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps | Ulta Lab Tests","description":"Cancer blood tests and tumor marker tests explained: learn why cancer screening blood tests have limits and how results guide follow-up care.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/","og_locale":"en_US","og_type":"article","og_title":"Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps","og_description":"Cancer blood tests and tumor marker tests explained: learn why cancer screening blood tests have limits and how results guide follow-up care.","og_url":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/","og_site_name":"Ulta Lab Tests","article_publisher":"https:\/\/facebook.com\/ultalabtests","article_published_time":"2026-08-11T18:39:39+00:00","article_modified_time":"2026-08-12T04:33:23+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/02-cancer-blood-tests-tumor-markers-square-hero.webp","type":"image\/webp"}],"author":"John R","twitter_card":"summary_large_image","twitter_misc":{"Written by":"John R","Est. reading time":"40 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/#article","isPartOf":{"@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/"},"author":{"name":"John R","@id":"https:\/\/www.ultalabtests.com\/blog\/#\/schema\/person\/e9af1f4fe34b68909911dc95c313ed6a"},"headline":"Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps","datePublished":"2026-08-11T18:39:39+00:00","dateModified":"2026-08-12T04:33:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/"},"wordCount":8237,"commentCount":0,"publisher":{"@id":"https:\/\/www.ultalabtests.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/02-cancer-blood-tests-tumor-markers-square-hero.webp?fit=1200%2C1200&quality=100&ssl=1","keywords":["abnormal cancer marker","AFP test","alpha-fetoprotein","beta-2 microglobulin","blood tests for cancer","CA 19-9 test","CA-125 test","cancer biomarkers","cancer blood test results","cancer blood tests","cancer diagnostic support","cancer follow-up testing","cancer genomics","cancer lab test preparation","cancer marker interpretation","cancer monitoring tests","cancer recurrence monitoring","cancer risk assessment","cancer screening blood tests","cancer screening guidelines","cancer screening limitations","cancer treatment monitoring","carcinoembryonic antigen","cbc test","CEA test","circulating tumor DNA","CMP test","colorectal cancer monitoring","complete blood count","Comprehensive Metabolic Panel","ctDNA","Direct-Access Lab Testing","elevated tumor marker","false-negative tumor marker","false-positive tumor marker","free light chains","free PSA","genetic cancer risk","germ-cell tumor markers","hCG tumor marker","hereditary cancer testing","imaging and biopsy","kappa lambda ratio","lactate dehydrogenase","LDH test","liquid biopsy","liver cancer tumor marker","lymphoma monitoring","MCED tests","molecular residual disease","monoclonal gammopathy","multi-cancer early detection","multiple myeloma testing","noncancer causes of elevated tumor markers","oncology lab tests","organ function testing","ovarian cancer monitoring","ovarian cancer tumor marker","pancreatic cancer monitoring","pancreatic cancer tumor marker","percent free PSA","plasma cell disorder testing","prostate cancer monitoring","Prostate cancer screening","PSA test","quantitative hCG","serum immunofixation","serum protein electrophoresis","specialist-directed testing","SPEP test","total PSA","treatment safety testing","tumor marker tests","tumor marker trends","tumor markers"],"articleSection":["Breast Cancer","Breast Health","Cancer","Cancer","Cancer and Tumor Markers - Men","Cancer and Tumor Markers - Women","Cervical Cancer","Colon and Rectal Cancer","Lab Testing Knowledge Center","Lab Testing Knowledge Center","Men's Health","Ovarian Cancer","Pancreatic Cancer","Prostate","Prostate Cancer","Testicular Cancer","Women's Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/","url":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/","name":"Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps | Ulta Lab Tests","isPartOf":{"@id":"https:\/\/www.ultalabtests.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/#primaryimage"},"image":{"@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/02-cancer-blood-tests-tumor-markers-square-hero.webp?fit=1200%2C1200&quality=100&ssl=1","datePublished":"2026-08-11T18:39:39+00:00","dateModified":"2026-08-12T04:33:23+00:00","description":"Cancer blood tests and tumor marker tests explained: learn why cancer screening blood tests have limits and how results guide follow-up care.","breadcrumb":{"@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/#primaryimage","url":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/02-cancer-blood-tests-tumor-markers-square-hero.webp?fit=1200%2C1200&quality=100&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/02-cancer-blood-tests-tumor-markers-square-hero.webp?fit=1200%2C1200&quality=100&ssl=1","width":1200,"height":1200,"caption":"Cancer-related blood testing is most useful when it answers a defined clinical question and is reviewed with other evidence."},{"@type":"BreadcrumbList","@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Ulta Lab Tests","item":"https:\/\/www.ultalabtests.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Cancer","item":"https:\/\/www.ultalabtests.com\/blog\/category\/cancer\/"},{"@type":"ListItem","position":3,"name":"Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps"}]},{"@type":"WebSite","@id":"https:\/\/www.ultalabtests.com\/blog\/#website","url":"https:\/\/www.ultalabtests.com\/blog\/","name":"Ulta Lab Tests","description":"You Order the Test. We&#039;ll Do the Rest!","publisher":{"@id":"https:\/\/www.ultalabtests.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ultalabtests.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ultalabtests.com\/blog\/#organization","name":"Ulta Lab Tests","url":"https:\/\/www.ultalabtests.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ultalabtests.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2023\/02\/logo.png?fit=405%2C79&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2023\/02\/logo.png?fit=405%2C79&ssl=1","width":405,"height":79,"caption":"Ulta Lab Tests"},"image":{"@id":"https:\/\/www.ultalabtests.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/ultalabtests","http:\/\/www.linkedin.com\/company\/3335617"]},{"@type":"Person","@id":"https:\/\/www.ultalabtests.com\/blog\/#\/schema\/person\/e9af1f4fe34b68909911dc95c313ed6a","name":"John R","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d48f9c8356694121fd9e2793e13d6aa6855e5df11f9b14f7a872b4ea554581fb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d48f9c8356694121fd9e2793e13d6aa6855e5df11f9b14f7a872b4ea554581fb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d48f9c8356694121fd9e2793e13d6aa6855e5df11f9b14f7a872b4ea554581fb?s=96&d=mm&r=g","caption":"John R"}}]}},"featured_image_src":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/02-cancer-blood-tests-tumor-markers-square-hero.webp?resize=600%2C400&quality=100&ssl=1","featured_image_src_square":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/02-cancer-blood-tests-tumor-markers-square-hero.webp?resize=600%2C600&quality=100&ssl=1","author_info":{"display_name":"John R","author_link":"https:\/\/www.ultalabtests.com\/blog\/author\/johnroehmultalabtests-com\/"},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2026\/08\/02-cancer-blood-tests-tumor-markers-square-hero.webp?fit=1200%2C1200&quality=100&ssl=1","_links":{"self":[{"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/posts\/2994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/comments?post=2994"}],"version-history":[{"count":0,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/posts\/2994\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/media\/3349"}],"wp:attachment":[{"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/media?parent=2994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/categories?post=2994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/tags?post=2994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}